
Article 1 

1. The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
2. However, the health claims referred to in paragraph 1 used prior to the entry into force of this Regulation, may continue to be used for a maximum period of six months after the entry into force of this Regulation.
Article 2 
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 29 October 2014.
For the Commission
The President
José Manuel BARROSO
ANNEX

Application — Relevant provisions of Regulation (EC) No 1924/2006 Nutrient, substance, food or food category Claim EFSA opinion reference
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data Zinc Prevents bad breath by neutralising of volatile sulphur compounds (VSC) in the mouth and oral cavity. Q-2010-01092
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data Yestimun® Daily administration of Yestimun® helps to maintain the body's defence against pathogens. Q-2012-00761
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data Transitech® Improves transit and durably regulates it. Q-2013-00087
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data Bimuno® GOS Regular daily consumption of 1,37 g galacto-oligosaccharides from Bimuno® may reduce abdominal discomfort. Q-2012-01007
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data Lactobacillus rhamnosus GG Lactobacillus rhamnosus GG for maintaining normal defecation during oral antibiotic treatment. Q-2013-00015
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data VeriSol®P Characteristic collagen peptide mixture (collagen hydrolysate) having a beneficial physiological effect on the maintenance of skin health, as indicated by an increased skin elasticity and a reduction of wrinkles volume, by contributing to a normal collagen and elastin synthesis. Q-2012-00839
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data Proanthocyanidins in Urell® Proanthocyanidins from Urell® contribute to support defence against bacterial pathogens in the lower urinary tract Q-2012-00700
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data Preservation® Improves the physiological response to stress by accelerating the appearance of heat shock proteins (HSPs) and maintains an effective level of HSPs to ensure that the organism is primed should the cell encounter further stress. Q-2013-00021